Abstract
Aromatase activity is absent in normal endometrium. In contrast, aromatase is expressed aberrantly in endometriosis, which gives rise to strikingly high levels of aromatase activity in this tissue. Both aromatase expression and activity are stimulated by PGE2. This results in local production of estrogen, which induces PGE2 formation and establishes a positive feedback cycle. Another abnormality in endometriosis, that is, deficient 17β-HSD type 2 expression, impairs the inactivation of estradiol to estrone. These molecular aberrations collectively favor accumulation of increasing quantities of estradiol and PGE2 in endometriosis. The clinical relevance of these findings was exemplified by the successful treatment of an unusually aggressive case of postmenopausal endometriosis using an aromatase inhibitor.
Original language | English (US) |
---|---|
Pages (from-to) | 75-85 |
Number of pages | 11 |
Journal | Annals of the New York Academy of Sciences |
Volume | 955 |
DOIs | |
State | Published - 2002 |
Keywords
- 17β-hydroxysteroid dehydrogenase type 2
- Aromatase
- Aromatase inhibitor
- Endometriosis
- Estrogen
- Estrogen biosynthesis
- Estrogen metabolism
- Osteoporosis
- Progesterone
- Steroidogenesis
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- General Neuroscience
- History and Philosophy of Science